Impact Factor 5.206 | CiteScore 4.82
More on impact ›

Original Research ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Cell Dev. Biol. | doi: 10.3389/fcell.2019.00238

Silencing of ARL14 Gene Induces Lung Adenocarcinoma Cells to a Dormant State

Fei Guo1, Dexiao Yuan1, Junlin Zhang1, Hang Zhang1, Chen Wang1, Lin Zhu1, Jianghong Zhang1, Yan Pan1* and  Chunlin Shao1, 2*
  • 1Institute of Radiation Medicine, Fudan University, China
  • 2Fudan University, China

Recently, a growing number of ADP ribosylation factor (ARF) family members has been suggested to be critical in tumorigenesis. However, the effects of most ARF members on lung adenocarcinoma pathogenesis are still not well disclosed yet. In this study, ARF-like GTPase 14 (ARL14) was screened as an important prognostic factor of lung adenocarcinoma from The Cancer Genome Atlas (TCGA) database and validated by our in vitro experiments. It was found that silencing of ARL14 gene inhibited cell proliferation and the abilities of cell migration and invasion, and it also attenuated radiation damage of lung adenocarcinoma cells but had no effect on the proliferation of normal lung cells. Notably, ARL14 siRNA blocked the extracellular signal-regulated kinase (ERK)/p38 signaling pathway and induced cell cycle arrest in G0 phase, ultimately leading to cell dormancy. Moreover, ARL14 siRNA enhanced the expression of cell death activator DFFA-like effector (CIDEC) that had opposite roles in cell proliferation and migration to ALR14. Collectively, our results suggest that ARL14 has an important role in the pathogenesis of lung adenocarcinoma through CIDEC/ERK/p38 signaling pathway, and thus it could be applied as a new candidate of prognosis indicator and/or therapeutic target of lung adenocarcinoma.

Keywords: ARL14, CIDEC, ERK/p38, Lung cancer dormancy, Radiation

Received: 27 Aug 2019; Accepted: 01 Oct 2019.

Copyright: © 2019 Guo, Yuan, Zhang, Zhang, Wang, Zhu, Zhang, Pan and Shao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence:
Dr. Yan Pan, Institute of Radiation Medicine, Fudan University, Shanghai, 2094, China,
Prof. Chunlin Shao, Fudan University, Shanghai, China,